Share This Page
Drug Price Trends for PAROXETINE CR
✉ Email this page to a colleague
Average Pharmacy Cost for PAROXETINE CR
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| PAROXETINE CR 12.5 MG TABLET | 60505-1316-03 | 0.46601 | EACH | 2025-04-23 |
| PAROXETINE CR 25 MG TABLET | 60505-1317-03 | 0.40901 | EACH | 2025-04-23 |
| PAROXETINE CR 37.5 MG TABLET | 60505-1318-03 | 0.50571 | EACH | 2025-04-23 |
| PAROXETINE CR 12.5 MG TABLET | 60505-1316-03 | 0.47139 | EACH | 2025-03-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Paroxetine CR
Introduction
Paroxetine CR, a controlled-release formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine, is widely used for treating depression, anxiety, and other psychiatric conditions. This analysis will delve into the market dynamics, efficacy, tolerability, and cost implications of Paroxetine CR, providing insights into its current market position and future price projections.
Efficacy and Tolerability
Paroxetine CR has been shown to be an effective and well-tolerated antidepressant. Clinical trials have demonstrated that it exhibits symptomatic improvement as early as week 1, with significant reductions in depressive symptoms and anxiety[1][4].
Early Symptomatic Improvement
Studies have indicated that Paroxetine CR leads to improved mood and reduced psychic anxiety symptoms from the first week of treatment, comparable to or even surpassing the immediate-release (IR) formulation[1].
Adverse Event Profile
The controlled-release formulation is associated with lower rates of early-onset nausea and other adverse events compared to the IR version. For instance, the incidence of nausea was significantly lower for Paroxetine CR (14%) than for Paroxetine IR (23%)[1][4].
Market Position and Usage
Paroxetine CR is a preferred option in the SSRI market due to its favorable tolerability profile and economic benefits.
Patient Compliance
Patients on Paroxetine CR are more likely to remain on therapy for at least 6 months compared to those on IR SSRIs, which contributes to lower healthcare resource costs[3].
Diagnostic Cohorts
The drug is effective across various diagnostic cohorts, including patients with anxiety disorders, depression, and comorbid anxiety and depression. It has been shown to have lower medical costs in all these cohorts compared to IR SSRIs[3].
Cost Analysis
The cost of Paroxetine CR is a significant factor in its market analysis.
Current Pricing
As of the latest data, the cost for a 30-tablet supply of Paroxetine CR 12.5 mg oral tablets can range from approximately $329 to $342, depending on the pharmacy and any available discounts or coupons[2].
Generic Version
A generic version of Paroxetine CR is available, which significantly reduces the cost, making it more accessible to patients. The generic version can cost as low as $29.90 for 30 tablets[2].
Economic Benefits
Paroxetine CR offers several economic advantages over IR SSRIs.
Lower Medical Costs
Studies have shown that patients receiving Paroxetine CR have 8.7% lower 6-month medical costs compared to those receiving IR SSRIs. This difference is even more pronounced in patients with comorbid anxiety and depression, where the costs are 15.9% lower[3].
Reduced Therapy Changes
The lower incidence of adverse events and higher patient compliance with Paroxetine CR result in fewer therapy changes, which further reduces overall healthcare costs[3].
Price Projections
Given the current market trends and the economic benefits of Paroxetine CR, here are some key points to consider for future price projections:
Market Demand
The demand for Paroxetine CR is likely to remain stable or increase due to its efficacy and tolerability. This demand, coupled with the availability of generic versions, may influence pricing strategies.
Price Increases
Recent data indicates a 9.9% increase in the prices of Paxil and Paxil CR oral tablets, which could be a trend to watch in the future. However, such increases are often balanced by discounts and rebates offered by manufacturers[5].
Competitive Landscape
The SSRI market is competitive, with several other drugs available. However, Paroxetine CR's unique profile of improved tolerability and lower medical costs positions it favorably against competitors.
Key Takeaways
- Efficacy and Tolerability: Paroxetine CR is effective and well-tolerated, with early symptomatic improvement and lower adverse event rates.
- Market Position: It is preferred due to its favorable tolerability profile and economic benefits.
- Cost Analysis: The drug is priced competitively, with significant cost savings when using the generic version.
- Economic Benefits: Lower medical costs and reduced therapy changes contribute to its economic advantages.
- Price Projections: Prices may see moderate increases, but the availability of generic versions and competitive market dynamics will influence pricing.
FAQs
What is Paroxetine CR used for?
Paroxetine CR is used for treating depression, anxiety disorders, dysautonomia, and other psychiatric conditions.
How does Paroxetine CR differ from Paroxetine IR?
Paroxetine CR has a controlled-release formulation that reduces early-onset nausea and other adverse events compared to the immediate-release version.
Is Paroxetine CR more expensive than other SSRIs?
While the brand version of Paroxetine CR can be costly, the generic version is significantly cheaper, making it a cost-effective option compared to some other SSRIs.
What are the economic benefits of using Paroxetine CR?
Paroxetine CR is associated with lower 6-month medical costs, reduced therapy changes, and higher patient compliance, all of which contribute to lower overall healthcare costs.
Are there any recent price changes for Paroxetine CR?
As of recent data, there has been a 9.9% increase in the prices of Paxil and Paxil CR oral tablets, but this can be mitigated by discounts and rebates.
Sources
- Efficacy and Tolerability of Controlled-Release and Immediate-Release Paroxetine in the Treatment of Major Depressive Disorder. The Journal of Clinical Psychopharmacology, 2002.
- Paxil CR Prices, Coupons, Copay Cards & Patient Assistance. Drugs.com.
- Differences in Total Medical Costs Across the SSRIs for the Treatment of Depression and Anxiety. The American Journal of Managed Care, 2005.
- Safety and Effectiveness of Controlled-Release Paroxetine in Routine Clinical Practice. Dovepress, 2015.
- The Latest Spooky, Scary Drug Price Changes. 46brooklyn Research, 2024.
More… ↓
